07:25 AM EST, 03/07/2025 (MT Newswires) -- Johnson & Johnson's ( JNJ ) Janssen-Cilag subsidiary has received marketing authorization in the UK for lazertinib combined with amivantamab to treat adults with a type of non-small cell lung cancer, the UK Medicines and Healthcare products Regulatory Agency said Thursday.

Lazertinib, marketed under the brand Lazcluze, in combination with amivantamab is to be used as treatment for non-small cell lung cancer that has spread and undergone changes called epidermal growth factor receptor, or EGFR, the regulator said.

The approval follows a clinical trial that showed the combination treatment led to an extended period without disease progression than lazertinib alone and against treatment with another cancer medicine, the regulator said.